"Over and over, trials evaluating PD-1/PD-L1 inhibitors in advanced prostate cancer have missed the mark. The failures have led to questions as to why—and have prompted oncologists to conclude that new treatment strategies are needed."

#Immunology #immunotherapy #checkpointinhibitors #prostatecancer

https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-NB2023-0017/718790/PD-1-Blockade-Falls-Short-Repeatedly-in-Prostate